Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

NCT00868608 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Inotuzumab Ozogamicin (CMC-544)

Sponsor

Pfizer

Collaborators

[object Object]